H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain–retina axis
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 20.10.2026. Verfasst von Dieu-Trang Fuchs und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain, Histones, Proteostasis. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health (NIH)/National Institute on Aging (NIA), NIA NIH HHS, The Snyder foundation.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Epigenetic dysregulation is increasingly linked to aging and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer's disease (AD) remains unclear. METHODS We quantified the repressive epigenetic mark histone H3 lysine 9 trimethylation (H3K9me3) in post mortem retinas and brains from donors spanning normal cognition, mild cognitive impairment, and AD dementia. Using a multi‐enzyme methyltransferase panel, we characterized the in vitro inhibitory activity of ETP69, an epidithiodiketopiperazine, against suppressor of variegation 3‐9 homologue 1 (SUV39H1) and other methyltransferases. In two transgenic AD mouse models (APPswe/PS1dE9 and APPswe/tauP301L/PS1 tm1Mpm ), we assessed ETP69 effects on cerebral H3 methylation, behavior, AD‐like pathology, synaptic integrity, and proteomic profiles. RESULTS H3K9me3 increased early across the AD continuum in both brain and retina, correlating with cognitive impairment and neuropathological burden. H3K9me3 levels were strongly correlated between matched brains and retinas ( r = 0.72, p = 0.0002). ETP69 substantially inhibited SUV39H1 and several other methyltransferases in cell‐free assays, while consistently reducing cerebral H3K9me3 in vivo relative to other histone marks assessed. In mice, pharmacological H3K9me3 reduction mitigated AD‐like pathology, preserved synapses, and improved short‐ and long‐term cognitive and visual performance. Proteomics revealed that H3K9me3 derepression re‐established retinal and brain proteostasis and remodeled innate immune pathways and brain‐derived neurotrophic factor/nerve growth factor‐inducible protein (BDNF/VGF)–granin signaling. DISCUSSION This study identifies H3K9me3 accumulation as a shared, reversible epigenetic contributor to AD across the retina–brain axis; its reduction represents a promising disease‐modifying strategy, and the retina may provide an accessible readout of brain epigenetic dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Macquarie University, Sydney, New South Wales, Australia.
- Department of Psychiatry and The Behavioral Sciences, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Department of Environmental and Occupational Health, College of Health Sciences, University of California, Irvine, California, USA.
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada.
- Department of Cancer Biology and Molecular Medicine, City of Hope National Medical Center, Duarte, California, USA.
ORCID-Profile: Maya Koronyo-Hamaoui
Förderung
- National Institutes of Health (NIH)/National Institute on Aging (NIA)
- NIA NIH HHS
- The Snyder foundation
- The Health Effects and Brain Tumor Foundation
Zitieren
APA
Fuchs, D. T., Vit, J. P., Rentsendorj, A., Koronyo, Y., Sheyn, J., Gaire, B. P., Shahin, S., Shi, H., Chepurna, O., Davis, M. R., Wilson, J. W., Graham, S. L., Gupta, V. K., Schneider, L. S., Kleinman, M. T., Sun, T., Fahnestock, M., Horne, D. A., Mirzaei, M., …, & Koronyo-Hamaoui, M. (2026). H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain–retina axis. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71918
Vancouver
Fuchs DT, Vit JP, Rentsendorj A, Koronyo Y, Sheyn J, Gaire BP, et al. H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain–retina axis. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71918
BibTeX
@article{Fuchs2026,
author = {Fuchs, Dieu-Trang and Vit, Jean-Philippe and Rentsendorj, Altan and Koronyo, Yosef and Sheyn, Julia and Gaire, Bhakta Prasad and Shahin, Saba and Shi, Haoshen and Chepurna, Oksana and Davis, Miyah R and Wilson, Jered W and Graham, Stuart L and Gupta, Vivek K and Schneider, Lon S and Kleinman, Michael T and Sun, Tao and Fahnestock, Margaret and Horne, David A and Mirzaei, Mehdi and Black, Keith L and Koronyo-Hamaoui, Maya},
title = {H3K9me3 inhibition reverses Alzheimer's progression by restoring synaptic and immune proteostasis across the brain–retina axis},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {10},
doi = {10.1002/alz.71918}
}
EUVIMED